Methodological considerations for designing and conducting open-label placebo trials
Authors:
- Helena HartmannHHHelena Hartmann
- Diana MüßgensDMDiana Müßgens
- Livia AsanLALivia Asan
- Aleksandrina SkvortsovaASAleksandrina Skvortsova
- Julian Kleine-BorgmannJKJulian Kleine-Borgmann
- Katharina SchmidtKSKatharina Schmidt
- Aurore FernandezAFAurore Fernandez
- Jules PhalipJPJules Phalip
- Johannes WesselsJWJohannes Wessels
- Marco ValerioMVMarco Valerio
- Meike Shedden-MoraMSMeike Shedden-Mora
- Ulrike BingelUBUlrike Bingel
Open Access
- 10 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
Abstract
In pain and other research fields, placebos have traditionally been associated with deception, although harnessing placebo effects does not necessarily require deception. Open-label placebos (OLPs) represent a novel approach in which inert treatments are administered openly and transparently, allowing patients to knowingly receive an inert treatment while still experiencing therapeutic benefits (eg, pain relief). As OLP research grows, concerns have been raised regarding methodological rigor and the unique challenges posed by unblinded designs in both experimental and clinical contexts. Given the inherent transparency regarding treatment group allocation in OLP trials, particular attention is needed when defining appropriate control groups, implementing feasible blinding strategies, and providing a treatment rationale to adequately explain OLPs. Addressing these challenges is crucial to advancing both the scientific understanding of the psychoneurobiological mechanisms underlying OLP effects and their clinical relevance in pain. In this review, we outline key methodological considerations for designing and conducting OLP studies in pain research and beyond, providing guidance on control group selection, blinding strategies, and reporting standards. In addition, we integrate insights from the patient advisory board of the transregional Collaborative Research Center (CRC/TRR) 289 “Treatment Expectation” to incorporate patient perspectives on the feasibility and acceptability of OLPs. Aligning study designs with patient needs and expectations may foster a more meaningful, patient-centered approach to OLP research. By combining methodological guidance and emphasizing patient-centered insights, this review aims to enhance the quality, relevance, and clinical translation of OLP research in pain.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (Project-ID 422744262)
This publication has 133 references indexed in Scilit:
- Can Nocebo Effects Be Reduced via Open‐ and Closed‐Label Counterconditioning?European journal of pain, 2026
- Open-Label Placebos as Adjunct for the Preventive Treatment of MigraineJAMA Network Open, 2025
- Open-Label Placebo Injection for Chronic Back Pain With Functional NeuroimagingJAMA Network Open, 2024
- Change in pain expectations but no open‐label placebo analgesia: An experimental study using the heat pain paradigmEuropean journal of pain, 2023
- Rethinking placebo: Exploring the effectiveness of open‐label placebosEuropean journal of pain, 2023
- If only they knew! A non‐inferiority randomized controlled trial comparing deceptive and open‐label placebo in healthy individualsEuropean journal of pain, 2023
- Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use DisorderJAMA Network Open, 2023
- Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel SyndromeJAMA Pediatrics, 2022
- Assessing the unwanted: A systematic review of instruments used to assess negative effects of psychotherapyBrain and Behavior, 2019
- Challenges of differential placebo effects in contemporary medicine: The example of brain stimulationAnnals of Neurology, 2018